Beneficial effects of novel antagonists of GHRH in different models of Alzheimersts's disease

Aging

Volumn 4, Issue 11, 2012, Pages 755-767

  Jaszberenyi, Miklos ^a,b   Rick, Ferenc G ^a   Szalontay, Luca ^a   Block, Norman L ^a,b   Zarandi, Marta ^a,b   Cai, Ren Zhi ^a,b   Schally, Andrew V ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

5XFAD mice; Alzheimer's disease; GHRH; Growth hormone releasing hormone; HCN 2 cell line; Morris water maze; Transgenic model

Indexed keywords

EID: 84872548672     PISSN: 19454589     EISSN: None     Source Type: Journal    
DOI: 10.18632/aging.100504     Document Type: Article

References (62)

1. Querfurth HW and LaFerla FM. Alzheimer's disease. N Engl J Med. 2010; 362:329-344.
2. Zheng H and Koo EH. The amyloid precursor protein: beyond amyloid. Mol Neurodegener. 2006; 1:5.
3. Reitz C, Brayne C and Mayeux R. Epidemiology of Alzheimer disease. Nat Rev Neurol. 2011; 7:137-152.
4. Sadow TF and Rubin RT. Effects of hypothalamic peptides on the aging brain. Psychoneuroendocrinology. 1992; 17:293-314.
5. Frisardi V, Solfrizzi V, Seripa D, Capurso C, Santamato A, Sancarlo D, Vendemiale G, Pilotto A and Panza F. Metaboliccognitive syndrome: a cross-talk between metabolic syndrome and Alzheimer's disease. Ageing Res Rev. 2010; 9:399-417.
6. Telegdy G, Tanaka M and Schally AV. Effects of the LHRH antagonist Cetrorelix on the brain function in mice. Neuropeptides. 2009; 43:229-234.
7. Telegdy G, Tanaka M and Schally AV. Effects of the growth hormone-releasing hormone (GH-RH) antagonist on brain functions in mice. Behav Brain Res. 2011; 224:155-158.
8. Meijer OC, Topic B, Steenbergen PJ, Jocham G, Huston JP and Oitzl MS. Correlations between hypothalamus-pituitary-adrenal axis parameters depend on age and learning capacity. Endocrinology. 2005; 146:1372-1381.
9. Telegdy G, Adamik A, Tanaka M and Schally AV. Effects of the LHRH antagonist Cetrorelix on affective and cognitive functions in rats. Regul Pept. 2010; 159:142-147.
10. Telegdy G and Schally AV. Involvement of neurotransmitters in the action of growth hormone-releasing hormone antagonist on passive avoidance learning. Behav Brain Res. 2012.
11. Banks WA, Morley JE, Farr SA, Price TO, Ercal N, Vidaurre I and Schally AV. Effects of a growth hormone-releasing hormone antagonist on telomerase activity, oxidative stress, longevity, and aging in mice. Proc Natl Acad Sci U S A. 2010; 107:22272-22277.
12. Hallschmid M, Wilhelm I, Michel C, Perras B and Born J. A role for central nervous growth hormone-releasing hormone signaling in the consolidation of declarative memories. PLoS One. 2011; 6:e23435.
13. Piriz J, Muller A, Trejo JL and Torres-Aleman I. IGF-I and the aging mammalian brain. Exp Gerontol. 2011; 46:96-99.
14. Cohen E and Dillin A. The insulin paradox: aging, proteotoxicity and neurodegeneration. Nature reviews Neuroscience. 2008; 9:759-767.
15. Cohen E, Paulsson JF, Blinder P, Burstyn-Cohen T, Du D, Estepa G, Adame A, Pham HM, Holzenberger M, Kelly JW, Masliah E and Dillin A. Reduced IGF-1 signaling delays ageassociated proteotoxicity in mice. Cell. 2009; 139:1157-1169.
16. Fernandez AM and Torres-Aleman I. The many faces of insulin-like peptide signalling in the brain. Nat Rev Neurosci. 2012; 13:225-239.
17. Sims-Robinson C, Kim B, Rosko A and Feldman EL. How does diabetes accelerate Alzheimer disease pathology? Nat Rev Neurol. 2010; 6:551-559.
18. Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, Berry R and Vassar R. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci. 2006; 26:10129-10140.
19. Schally AV, Varga JL and Engel JB. Antagonists of growthhormone-releasing hormone: an emerging new therapy for cancer. Nat Clin Pract Endocrinol Metab. 2008; 4:33-43.
20. Varga JL, Schally AV, Horvath JE, Kovacs M, Halmos G, Groot K, Toller GL, Rekasi Z and Zarandi M. Increased activity ofantagonists of growth hormone-releasing hormone substituted at positions 8, 9, and 10. Proc Natl Acad Sci U S A. 2004; 101:1708-1713.
21. Kovacs M, Zarandi M, Halmos G, Groot K and Schally AV. Effects of acute and chronic administration of a new potent antagonist of growth hormone-releasing hormone in rats: mechanisms of action. Endocrinology. 1996; 137:5364-5369.
22. Barabutis N and Schally AV. Growth hormone-releasing hormone: extrapituitary effects in physiology and pathology. Cell Cycle. 2010; 9:4110-4116.
23. Rick FG, Schally AV, Block NL, Nadji M, Szepeshazi K, Zarandi M, Vidaurre I, Perez R, Halmos G and Szalontay L. Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia. Proc Natl Acad Sci U S A. 2011; 108:3755-3760.
24. Kiaris H, Chatzistamou I, Papavassiliou AG and Schally AV. Growth hormone-releasing hormone: not only a neurohormone. Trends Endocrinol Metab. 2011; 22:311-317.
25. Rick FG, Seitz S, Schally AV, Szalontay L, Krishan A, Datz C, Stadlmayr A, Buchholz S, Block NL and Hohla F. GHRH antagonist when combined with cytotoxic agents induces S-phase arrest and additive growth inhibition of human colon cancer. Cell Cycle. 2012; 11:4203-4210.
26. Perez R, Schally AV, Vidaurre I, Rincon R, Block NL and Rick FG. Antagonists of growth hormone-releasing hormone suppress in vivo tumor growth and gene expression in triple negative breast cancers. Oncotarget. 2012; 3:988-997.
27. Stangelberger A, Schally AV, Rick FG, Varga JL, Baker B, Zarandi M and Halmos G. Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild-type p53 and decrease in p21 and mutant p53 proteins. Prostate. 2012; 72:555-565.
28. Rick FG, Szalontay L, Schally AV, Block NL, Nadji M, Szepeshazi K, Vidaurre I, Zarandi M, Kovacs M and Rekasi Z. Combining growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist greatly augments benign prostatic hyperplasia shrinkage. J Urol. 2012; 187:1498-1504.
29. Bartke A. Can growth hormone (GH) accelerate aging? Evidence from GH-transgenic mice. Neuroendocrinology. 2003; 78:210-216.
30. Laron Z. Do deficiencies in growth hormone and insulin-like growth factor-1 (IGF-1) shorten or prolong longevity? Mech Ageing Dev. 2005; 126:305-307.
31. Falleti MG, Maruff P, Burman P and Harris A. The effects of growth hormone (GH) deficiency and GH replacement on cognitive performance in adults: a meta-analysis of the current literature. Psychoneuroendocrinology. 2006; 31:681-691.
32. Rhein V, Baysang G, Rao S, Meier F, Bonert A, Muller-Spahn F and Eckert A. Amyloid-beta leads to impaired cellular respiration, energy production and mitochondrial electron chain complex activities in human neuroblastoma cells. Cell Mol Neurobiol. 2009; 29:1063-1071.
33. Micheau J and Marighetto A. Acetylcholine and memory: a long, complex and chaotic but still living relationship. Behav Brain Res. 2011; 221:424-429.
34. Cummings JL. Alzheimer's disease. N Engl J Med. 2004; 351:56-67.
35. Telegdy G and Schally AV. Neurotransmitter-mediated action of an antagonist of growth hormone-releasing hormone on anxiolysis in mice. Behav Brain Res. 2012; 233:232-236.
36. Tanaka M, Schally AV and Telegdy G. Neurotransmission of the antidepressant-like effects of the growth hormone-releasing hormone antagonist MZ-4-71. Behav Brain Res. 2012; 228:388-391.
37. Chen F, Hasegawa H, Schmitt-Ulms G, Kawarai T, Bohm C, Katayama T, Gu Y, Sanjo N, Glista M, Rogaeva E, Wakutani Y, Pardossi-Piquard R, Ruan X, et al. TMP21 is a presenilin complex component that modulates gamma-secretase but not epsilonsecretase activity. Nature. 2006; 440:1208-1212.
38. Nixon RA. A "protease activation cascade" in the pathogenesis of Alzheimer's disease. Ann N Y Acad Sci. 2000; 924:117-131.
39. Hyman BT, Strickland D and Rebeck GW. Role of the lowdensity lipoprotein receptor-related protein in beta-amyloid metabolism and Alzheimer disease. Arch Neurol. 2000; 57:646-650.
40. Bamburg JR and Bloom GS. Cytoskeletal pathologies of Alzheimer disease. Cell Motil Cytoskeleton. 2009; 66:635-649.
41. Martin L, Magnaudeix A, Wilson CM, Yardin C and Terro F. The new indirubin derivative inhibitors of glycogen synthase kinase-3, 6-BIDECO and 6-BIMYEO, prevent tau phosphorylation and apoptosis induced by the inhibition of protein phosphatase-2A by okadaic acid in cultured neurons. J Neurosci Res. 2011; 89:1802-1811.
42. Lazarov O and Marr RA. Neurogenesis and Alzheimer's disease: at the crossroads. Exp Neurol. 2010; 223(2):267-281.
43. Woo HN, Park JS, Gwon AR, Arumugam TV and Jo DG. Alzheimer's disease and Notch signaling. Biochem Biophys Res Commun. 2009; 390(4):1093-1097.
44. Saitoh T, Horsburgh K and Masliah E. Hyperactivation of signal transduction systems in Alzheimer's disease. Ann N Y Acad Sci. 1993; 695:34-41.
45. Diniz BS and Teixeira AL. Brain-derived neurotrophic factor and Alzheimer's disease: physiopathology and beyond. Neuromolecular Med. 2011; 13:217-222.
46. Wu ZC, Yu JT, Li Y and Tan L. Clusterin in Alzheimer's disease. Adv Clin Chem. 2012; 56:155-173.
47. Chen YZ. APP induces neuronal apoptosis through APP-BP1-mediated downregulation of beta-catenin. Apoptosis. 2004; 9:415-422.
48. Chen DY, Stern SA, Garcia-Osta A, Saunier-Rebori B, Pollonini G, Bambah-Mukku D, Blitzer RD and Alberini CM. A critical role for IGF-II in memory consolidation and enhancement. Nature. 2011; 469:491-497.
49. Kovacs M, Schally AV, Varga JL and Zarandi M. Endocrine and antineoplastic actions of growth hormone-releasing hormone antagonists. Curr Med Chem. 2008; 15(4):314-321.
50. Vitiello MV, Moe KE, Merriam GR, Mazzoni G, Buchner DH and Schwartz RS. Growth hormone releasing hormone improves the cognition of healthy older adults. Neurobiol Aging. 2006; 27:318-323.
51. Baker LD, Barsness SM, Borson S, Merriam GR, Friedman SD, Craft S and Vitiello MV. Effects of Growth Hormone-Releasing Hormone on Cognitive Function in Adults With Mild Cognitive Impairment and Healthy Older Adults: Results of a Controlled Trial. Arch Neurol. 2012:1-10.
52. Merriam GR, Schwartz RS and Vitiello MV. Growth hormonereleasing hormone and growth hormone secretagogues in normal aging. Endocrine. 2003; 22:41-48.
53. Blagosklonny MV. Rapamycin and quasi-programmed aging: four years later. Cell Cycle. 2010; 9:1859-1862.
54. Blagosklonny MV and Hall MN. Growth and aging: a common molecular mechanism. Aging. 2009; 1:357-362.
55. Blagosklonny MV. Once again on rapamycin-induced insulin resistance and longevity: despite of or owing to. Aging. 2012; 4:350-358.
56. Jaeger LB, Banks WA, Varga JL and Schally AV. Antagonists of growth hormone-releasing hormone cross the blood-brain barrier: a potential applicability to treatment of brain tumors. Proc Natl Acad Sci U S A. 2005; 102:12495-12500.
57. Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods. 1984; 11:47-60.
58. Gallagher M, Burwell R and Burchinal M. Severity of spatial learning impairment in aging: development of a learning index for performance in the Morris water maze. Behav Neurosci. 1993; 107:618-626.
59. Vorhees CV and Williams MT. Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat Protoc. 2006; 1:848-858.
60. Zhang Z, Drzewiecki GJ, Hom JT, May PC and Hyslop PA. Human cortical neuronal (HCN) cell lines: a model for amyloid beta neurotoxicity. Neurosci Lett. 1994; 177:162-164.
61. Pozsgai E, Schally AV, Halmos G, Rick F and Bellyei S. The inhibitory effect of a novel cytotoxic somatostatin analogue AN-162 on experimental glioblastoma. Horm Metab Res. 2010; 42:781-786.
62. Rick FG, Schally AV, Szalontay L, Block NL, Szepeshazi K, Nadji M, Zarandi M, Hohla F, Buchholz S and Seitz S. Antagonists of growth hormone-releasing hormone inhibit growth of androgenindependent prostate cancer through inactivation of ERK and Akt kinases. Proc Natl Acad Sci U S A. 2012; 109:1655-1660.